Cardiovascular Disease

Gene Therapy Program Expanded

Published in Gene Therapy Weekly, June 8th, 1998

Genzyme General, Cambridge, Massachusetts, announced an expansion of its cardiovascular gene therapy program through two separate agreements with scientists at St. Elizabeth's Medical Center, Boston, Massachusetts, and the Johns Hopkins University School of Medicine, Baltimore, Maryland.

Both agreements involve the development of gene therapy products to treat occlusive vascular disease, or blockage of the blood vessels of the heart and legs.

Occlusive vascular disease is commonly treated by either bypass surgery or angioplasty. Genzyme is seeking to develop treatments which either augment or supplement these established modes of therapy for...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1998-06-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry